In the third quarter of 2024, uniQure NV (0EE0.L) reported significant financial challenges, with a net income loss of $44.38 million, a 50.45% decrease year-over-year (YoY). Revenue was at $2.29 million, reflecting a staggering 79.44% decline from the previous quarter, but a notable increase of 62.54% YoY. Despite the revenue upswing, the operating losses highlight the ongoing expenses related to R&D efforts targeting innovative gene therapies, particularly for hemophilia B and Huntington’s disease. Management emphasized their commitment to advancing clinical trials, which are critical for long-term success and potential revenue streams.